ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

Stopped early · Not applicable

Conditions studied: Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension

In brief

The purpose of this study is to determine the effects of Angiotension Converting Enzyme Inhibitors (ACE-I) during surgery and in the immediate postoperative period for patients undergoing elective total hip or knee arthroplasty.

Key facts

Study ID

NCT01867047

Run by

Duke University

People needed

59

Starts

2013-06-01

Expected to finish

2016-06-24

Last updated by the study team

2017-09-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients electing to undergo primary or revision total hip or knee arthroplasty
• Currently taking an ACE-I

You may not qualify if…

• Trauma patients
• Immunosuppressed patients (HIV/AIDS, organ transplant recipients, chemotherapy patients, chronic steroid use)
• Patients with history of severe hypertension related illness such as hypertension associated with stroke or myocardial infarction
• Patients in who continuation of their ACE-I is expressly mandated by their prescribing physician

Where it is running

• Duke University — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.